Vertex Pharmaceuticals
American pharmaceutical company
VRTX Nasdaq
ISIN US92532F1003 SEC CIK 875320
Follow Vertex Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$3.4B
+11.8% vs same quarter last year
Net income
$653.6M
−39.6% vs same quarter last year
EPS, diluted
$2.56
−39% vs same quarter last year
Operating cash flow
$643.1M
−48.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $12B | $4B |
| FY24 | $11B | −$535.6M |
| FY23 | $9.9B | $3.6B |
| FY22 | $8.9B | $3.3B |
| FY21 | $7.6B | $2.3B |
| FY20 | $6.2B | $2.7B |
| FY19 | $4.2B | $1.2B |
| FY18 | $3B | $2.1B |
| FY17 | $2.5B | $263.5M |
| FY16 | $1.7B | −$112.1M |
| FY15 | $1B | −$556.3M |
| FY14 | $580.4M | −$738.6M |
| FY13 | $1.2B | −$445M |
| FY12 | $1.5B | −$107M |
| FY11 | $1.4B | $29.6M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 86.2% | 34.8% | 32.9% |
| FY24 | 86.1% | −2.1% | −4.9% |
| FY23 | 87.2% | 38.8% | 36.7% |
| FY22 | 87.9% | 48.2% | 37.2% |
| FY21 | 88.1% | 36.7% | 30.9% |
| FY20 | 88.1% | 46% | 43.7% |
| FY19 | 86.8% | 28.8% | 28.3% |
| FY18 | 86.6% | 20.8% | 68.8% |
| FY17 | 88.9% | 5% | 10.6% |
| FY16 | 87.6% | 0.6% | −6.6% |
| FY15 | 88.7% | −45.2% | −53.9% |
| FY14 | 93.2% | −119.3% | −127.2% |
| FY13 | 92.7% | −50.3% | −36.7% |
| FY12 | 84.5% | 3.1% | −7% |
| FY11 | 95.5% | 8.1% | 2.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $3.2B |
| FY24 | −$790.3M |
| FY23 | $3.3B |
| FY22 | $3.9B |
| FY21 | $2.4B |
| FY20 | $3B |
| FY19 | $1.5B |
| FY18 | $1.2B |
| FY17 | $745.5M |
| FY16 | $179.5M |
| FY15 | −$410.7M |
| FY14 | −$624.3M |
| FY13 | −$112.1M |
| FY12 | $196.7M |
| FY11 | $109.1M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $2B |
| FY24 | $1.2B |
| FY23 | $427.6M |
| FY22 | $0 |
| FY21 | $1.4B |
| FY20 | $539.1M |
| FY19 | $186M |
| FY18 | $350M |
| FY17 | $0 |
| FY16 | $0 |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Vertex Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Vertex Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 32.9% | −30.6% |
| FY24 | −4.9% | −47% |
| FY23 | 36.7% | −58% |
| FY22 | 37.2% | −80.4% |
| FY21 | 30.9% | −71.9% |
| FY20 | 43.7% | −62.2% |
| FY19 | 28.3% | −46.3% |
| FY18 | 68.8% | −49.6% |
| FY17 | 10.6% | −45.9% |
| FY16 | −6.6% | −36% |
| FY15 | −53.9% | −38.4% |
| FY14 | −127.2% | −35.5% |
| FY13 | −36.7% | −37.1% |
| FY12 | −7% | −29.1% |
| FY11 | 2.1% | −27.9% |